Setmelanotide, marketed by Rhythm Pharmaceuticals as IMCIVREE, is a cyclic peptide melanocortin-4 receptor (MC4R) agonist that restores signaling in patients whose MC4R-pathway hunger-and-energy-balance circuit is broken by genetic defects upstream of MC4R or by structural damage to the hypothalamus. The drug is the first approved targeted therapy for several rare genetic obesity syndromes and the first medication to treat acquired hypothalamic obesity following brain tumor surgery or trauma.
The FDA approved IMCIVREE in 2020 for POMC, PCSK1, and LEPR deficiency obesity, expanded the label to Bardet-Biedl Syndrome (BBS) in 2022, and added acquired hypothalamic obesity in March 2026 after the Phase 3 TRANSCEND trial showed an 18.4% placebo-adjusted BMI reduction at 52 weeks. Full TRANSCEND results were published in the New England Journal of Medicine on July 8, 2026, positioning the trial as the largest and longest placebo-controlled study ever conducted in acquired hypothalamic obesity. Q1 2026 IMCIVREE net product revenue hit $60.1M (up 59% YoY). At ENDO 2026 in Chicago, Rhythm presented seven setmelanotide abstracts across three indications: a 2.5-year long-term extension in acquired hypothalamic obesity (-18.9% mean BMI reduction), interim Phase 2 data in Prader-Willi Syndrome (3.0-3.1% BMI reduction with lean-mass preservation), and real-world Bardet-Biedl Syndrome outcomes from the 6-month RESTORE study. The Phase 3 EMANATE program in broader MC4R-pathway diseases missed its primary endpoint in May 2026, narrowing the indication-expansion runway.
Stories here cover setmelanotide trial readouts, commercial uptake, and the MC4R competitive set. See [[rhythm-pharmaceuticals]], [[mc4r]], and [[hypothalamic-obesity]] for adjacent threads.
LEO Pharma announced Tuesday August 18, 2026 an agreement to acquire worldwide rights to dersimelagon (formerly MT-7117) from Japanese drugmaker Mitsubishi Tanabe Pharma. Dersimelagon is a selective melanocortin-1 receptor (MC1R) agonist small-molecule compound being developed for erythropoietic protoporphyria (EPP) and X-linked erythropoietic protoporphyria (XLEPP), rare inherited photodermatoses in which patients develop severe skin pain and burning after light exposure. Dersimelagon is currently in Phase 3 trials across multiple rare photodermatoses indications. The mechanism: MC1R agonism stimulates skin cells (melanocytes) to produce more melanin, which absorbs light and reduces the pain-generating reaction to sun exposure that characterizes EPP. Dersimelagon represents an oral small-molecule alternative to the currently-approved injectable melanocortin-axis therapies including Clinuvel's Scenesse (afamelanotide, an alpha-MSH analog peptide administered as a subcutaneous implant for EPP, approved US 2019) and adjacent to Rhythm Pharmaceuticals' IMCIVREE (setmelanotide, an MC4R agonist peptide for rare genetic obesity syndromes and acquired hypothalamic obesity, approved US 2020 with the acquired hypothalamic obesity extension approved June 2026). The LEO Pharma acquisition extends the melanocortin therapeutic franchise landscape and positions LEO for a broader dermatology and rare-disease portfolio alongside its existing psoriasis and atopic dermatitis commercial franchises. Financial terms were not fully disclosed. The transaction adds to the growing melanocortin-axis drug development activity across peptide (afamelanotide, setmelanotide, melanotan II) and small-molecule (dersimelagon) modalities.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported on the August 4, 2026 Q2 2026 earnings call that the US launch of IMCIVREE (setmelanotide) in the newly-approved acquired hypothalamic obesity indication has recorded more than 400 patient start forms since FDA approval in late June 2026. Setmelanotide is a synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analog peptide that activates the melanocortin-4 receptor (MC4R) to produce appetite suppression; the peptide is administered as a daily subcutaneous injection. The launch ranks among the stronger rare-disease peptide launches of the year to date and extends the melanocortin-agonist franchise beyond the original rare genetic obesity syndromes (POMC, LEPR, PCSK1 deficiency) that IMCIVREE was initially approved for in 2020. The acquired hypothalamic obesity indication addresses patients with hypothalamic damage from brain tumors (particularly craniopharyngioma), radiation therapy, surgery, or trauma that disrupts normal melanocortin signaling and leads to severe obesity with dysfunctional appetite regulation. The therapeutic story is mechanistically adjacent to but distinct from the alpha-MSH gray-market use of melanotan II (which activates the same broader melanocortin receptor family for tanning and appetite suppression); setmelanotide has substantially more selectivity for MC4R specifically, an established safety monitoring program, and full FDA approval under the rare-disease pathway. IMCIVREE full-year 2026 revenue guidance is expected to reflect the acquired hypothalamic obesity launch trajectory.
Rhythm Pharmaceuticals announced Wednesday July 8, 2026 that Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE), a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in the New England Journal of Medicine. TRANSCEND is the largest and longest placebo-controlled clinical trial ever conducted in acquired hypothalamic obesity, a rare and severe metabolic condition caused by damage to the hypothalamus from tumors, surgery, radiation, or trauma. The publication documents weight and hunger improvements in adult and pediatric patients aged four years and older across the treatment arm versus placebo control. IMCIVREE is already FDA-approved as a once-daily subcutaneous injection for chronic weight management in adults and pediatric patients aged four and older with acquired hypothalamic obesity, as well as for syndromic or monogenic obesity in patients with confirmed loss-of-function variants. The NEJM publication follows the earlier Kalohexis confidential IPO filing (July 7-8) on the dual MC3R/MC4R melanocortin platform, sustaining momentum around melanocortin biology as the highest-profile non-GLP-1 obesity mechanism in commercial development.
Rhythm Pharmaceuticals (Nasdaq: RYTM) presented seven setmelanotide abstracts at ENDO 2026 covering three rare-disease patient populations. Christian Roth (Seattle Children's) reported 2.5-year Phase 2 + long-term extension data in acquired hypothalamic obesity showing -18.9% mean BMI reduction across all 11 participants. The PWS interim Phase 2 (June 13) reported across 17 patients (10 adult, 7 pediatric) showed 3.11% mean BMI reduction in adults and 3.00% in pediatric patients, with 8 of 10 baseline-hyperphagic patients hitting a 7-point HQ-CT reduction, and 4.19% fat-mass loss with 0.74% lean-mass gain across 16 DEXA evaluations. Two BBS late-breaking posters from Caroline Huber covered real-world hyperphagia and healthcare-utilization outcomes from the 6-month RESTORE study. All three indications reinforce the MC4R-agonist rationale for Phase 3.
Rhythm Pharmaceuticals reported Q1 2026 results May 5: setmelanotide (IMCIVREE) net product revenue of $60.1M, up from $37.7M a year earlier ($36.9M US, $23.2M ex-US), driven by 150+ new US start forms in acquired hypothalamic obesity following the FDA approval and the EU Marketing Authorization for the same indication; Japan's PMDA accepted the NDA for review. The MC4R-agonist peptide is the only commercial therapy for hypothalamic obesity. Offsetting the topline beat: the Phase 3 EMANATE trial in genetically caused MC4R-pathway diseases failed its primary endpoint in all four independent substudies, narrowing the indication-expansion runway. Net loss was $56.7M; cash $340.6M for 24+ months runway.
FDA approved setmelanotide (IMCIVREE), an MC4R agonist peptide, for reducing body weight in adults and children aged 4+. Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks.